



Ashort Review On Streptomyces Species

M .Shireesha

Department of microbiology

Siddhartha women's degree and PG college Kukatpally

Abstract

The genus *Streptomyces* is the largest and one of the most diverse group of actinobacteria, which are economically important as soil inhabitants. *Streptomyces* spp. are G+ filamentous bacteria known for their complex life cycle and the production of a large part of the secondary metabolites, including more than two-thirds of clinically used antibiotics. These organisms are also important in soil ecology, by actively degrading a wide range of organic matter and impacting the cycling of carbon and nitrogen. Recent developments in genome sequencing and synthetic biology have provided new possibilities for the activation of silent biosynthetic gene clusters (BGCs) in strains of *Streptomyces* with the aim of discovering novel bioactive compounds. In this review, we will describe the taxonomy and morphology/ecology of streptomyces and their ecophysiological functions, biotechnological significance and recent trends in research efforts for isolation of novel strains.

Introduction

Streptomyces is a bacterial genus of the phylum Actinobacteria and the family Streptomycetaceae. They are filamentous, aerobic, Gram-positive bacteria that have a high guanine-cytosine (G+C) content (68–78%) in DNA and complex multicellular morphology (Kämpfer, 2012). The number of validly published species of *Aurantimonas* to date is >600 (Parte et al., 2020).

They are mainly soil inhabitants and are important for the decomposition of organic matter with geosmin production being responsible for typical smell in soil (Seipke et al., 2012). Yet *Streptomyces* is more than just ecology. They are most important producers of secondary metabolites in the bacterial kingdom and to a large extent underlie the discovery of antibiotics, anticancer drugs, antifungals, immunosuppressants, and enzyme inhibitors (Berdy, 2012)

Review of literature

The genus *Streptomyces* belongs to the order Streptomycetales and family Streptomycetaceae (Kämpfer, 2012). Modally, organisms of the genus *Streptomyces* exhibit a filamentous growth in which substrate mycelium forages the solid medium and aerial mycelium that differentiates to form chains of spores (Kieser et al., 2000). Unlike mycetes they lack chitin in the cell walls but feature peptidoglycan with LL-diaminopimelic acid.

Ecological Role and Habitat

Members of the genus *Streptomyces* are saprophytic and can be found everywhere in terrestrial and aquatic environments. They participate in the degradation of recalcitrant organic matter including cellulose, lignin and chitin, contributing to soil fertility (van der Meij et al., 2017). Furthermore, some strains have been isolated as free from the rhizosphere (Amer and Abd-Alla, 2001). Some species also form beneficial for plants by stimulating growth and protecting the root against pathogens through antibiotic and plant hormone production.

Antibiotic and Secondary Metabolite Production

One of the striking features of these *Streptomyces*. Some and related species is their potential to produce great diversity. The ability to have made Known only a few secondary metabolites. These are clinically significant antibiotics, such as:

S. griseus Streptomycin (Schatz et al., 1944)

Tetracycline from *S. aureofaciens*

Erythromycin from *S. erythraea*

Chloramphenicol from *S. venezuelae*

Neomycin from *S. fradiae*

Avermectin from *S. avermitilis*

Genomics and Secondary Metabolism Regulation

Sequencing M145 revealed the first complete genome of a *Streptomyces* and over 20 BGCs (Bentley et al., 2002). Approaches in modern bioinformatics such as antiSMASH have meanwhile revealed hundreds of silent, newly so-called cryptic BGCs scattered across the various *Streptomyces* genomes (Medema et al., 2011).

Control of secondary metabolism is a complex process and overall is mediated by a network of global and pathway-specific regulators that integrate antibiotic formation together with morphological development.

Biotechnological and Industrial Applications

In addition to the above antibiotic production, *Streptomyces* produce many other enzymes or drug candidates like cellulases, proteases and xylanases used in pharmaceuticals, agriculture and food industries (Kieser et al., 2000). Compounds like rapamycin (*S. hygroscopicus*), tacrolimus (*S. tsukubaensis*), and clavulanic acid (*S. clavuligerus*) have changed the face of medicine with their immunosuppressive and β -lactamase inhibitor activities

Emerging Research and Genetic Engineering

Genome editing methods, such as CRISPR-Cas9, now allow researchers to wake up silent gene clusters and engineer *Streptomyces* strains to further produce metabolites (Huang et al., 2015). The development of synthetic biology tools has made it possible to reconstitute intricate biosynthetic pathways in heterologous hosts for the purpose of discovering novel antibiotics to address antimicrobial resistance (Rutledge & Challis, 2015).

Discussion

The *Streptomyces* will contribute to the ecological equilibrium and the biotechnological progress. Their distinct developmental biology and high biosynthetic capacities, make them excellent microbial factories for bioactive compound discovery. Nevertheless, many problems remain such as the difficulty in growing numerous strains in the laboratory, low yields of metabolites and complexity of the regulation of secondary metabolism (Chater, 2016).

More recently, the role of *Streptomyces* in sustainable agriculture as biofertilizers and biocontrol agents has been increasingly recognized (Viaene et al., 2016). Moreover, investigation of extremophilic *Streptomyces* sp. From the sea and desert have revealed new anticancer compounds with good biological activity (Subramani & Aalbersberg, 2012).

This potential will be realized through the use of integrated “omics” technologies (genomics, transcriptomics, proteomics, metabolomics). These tools enable a systems-level perspective of cellular function driven by systems metabolic engineering to ferrooxidans and beyond.

Conclusion

Streptomyces species are like a treasure trove of powerful compounds that have really made a big impact on medicine and biotechnology these days. They are super versatile and can adapt to different environments, which is probably why they’ve been so successful throughout evolution. Thanks to all the cool stuff happening in genomics and synthetic biology, we’re now in a great position to find even more antibiotics and treatments.

References

1. Baltz, R. H. (2017). Gifted microbes for genome mining and natural product discovery. *Journal of Industrial Microbiology & Biotechnology*, 44(4–5), 573–588.
2. Bentley, S. D., Chater, K. F., Cerdeño-Tárraga, A. M., Challis, G. L., Thomson, N. R., James, K. D., ... & Hopwood, D. A. (2002). Complete genome sequence of the model actinomycete *Streptomyces coelicolor* A3(2). *Nature*, 417(6885), 141–147.
3. Berdy, J. (2012). Thoughts and facts about antibiotics: Where we are now and where we are heading. *The Journal of Antibiotics*, 65(8), 385–395.
4. Chater, K. F. (2016). Recent advances in understanding *Streptomyces*. *F1000Research*, 5, 2795.
5. Huang, H., Zheng, G., Jiang, W., Hu, H., & Lu, Y. (2015). One-step high-efficiency CRISPR/Cas9-mediated genome editing in *Streptomyces*. *Acta Biochimica et Biophysica Sinica*, 47(4), 231–243.
6. Kämpfer, P. (2012). The family Streptomycetaceae, part I: Taxonomy. In *The Prokaryotes* (pp. 889–1010). Springer.
7. Kieser, T., Bibb, M. J., Buttner, M. J., Chater, K. F., & Hopwood, D. A. (2000). *Practical Streptomyces Genetics*. The John Innes Foundation.
8. Medema, M. H., Blin, K., Cimermancic, P., de Jager, V., Zakrzewski, P., Fischbach, M. A., ... & Breitling, R. (2011). antiSMASH: Rapid identification and analysis of secondary metabolite biosynthesis gene clusters. *Nucleic Acids Research*, 39(Web Server issue), W339–W346.
9. Parte, A. C., Sardà Carbasse, J., Meier-Kolthoff, J. P., Reimer, L. C., & Göker, M. (2020). List of Prokaryotic names with Standing in Nomenclature (LPSN) moves to the DSMZ. *International Journal of Systematic and Evolutionary Microbiology*, 70(11), 5607–5612.
10. Rutledge, P. J., & Challis, G. L. (2015). Discovery of microbial natural products by activation of silent biosynthetic gene clusters. *Nature Reviews Microbiology*, 13(8), 509–523.

11. Schatz, A., Bugie, E., & Waksman, S. A. (1944). Streptomycin, a substance exhibiting antibiotic activity against Gram-positive and Gram-negative bacteria. *Proceedings of the Society for Experimental Biology and Medicine*, 55(1), 66–69.
12. Seipke, R. F., Kaltenpoth, M., & Hutchings, M. I. (2012). *Streptomyces* as symbionts: An emerging and widespread theme? *Frontiers in Microbiology*, 3, 249.
13. Subramani, R., & Aalbersberg, W. (2012). Marine actinomycetes: An ongoing source of novel bioactive metabolites. *Microbiological Research*, 167(10), 571–580.
14. Van der Meij, A., Worsley, S. F., Hutchings, M. I., & van Wezel, G. P. (2017). Chemical ecology of antibiotic production by actinomycetes. *FEMS Microbiology Reviews*, 41(3), 392–416.
15. Viaene, T., Langendries, S., Beirinckx, S., Maes, M., & Goormachtig, S. (2016). *Streptomyces* as a plant's best friend? *FEMS Microbiology Ecology*, 92(8), fiw119.

